Share

De Tijd publishes Op-ed of Belgian signatories

Today, leading Belgian newspaper De Tijd published an Op-ed co-signed by several BSP signatories on the potential and future of Belgian and EU biotech.

The Belgian biotech sector is world class in terms of innovation and R&D and a key pillar of the economy. The authors argue that biotech in Belgium has considerable potential, especially in terms of access and commercialization.

The potential of Europe in the biotech domain is also undeniable. In order to stay competitive and guarantee European patients have access to lifechanging medicines, a favourable environment and common approach is needed.

#BiotechSocialPact

You can find the full Op-ed here and feel free to share our posts on LinkedIn and Twitter!

The Biotech Social Pact gathers CEOs and leaders of biotech and life sciences who are committed to working alongside high-level policymakers and health authorities to sustainably grow the biotech ecosystem whilst ensuring timely and widespread access to innovative treatments for patients and health systems across Europe. The Biotech Social Pact does not necessarily reflect the policies or positions of the agencies, organizations, employers, or companies with which the signatories are affiliated. United in upholding common principles and beliefs, our members are diverse assembly of leading organisations that are often not represented in trade associations, including pre- and early commercial companies, venture capital firms and individual industry leaders. The BSP is not a trade association and coexists alongside existing biopharma trade associations. It aims at offering a supporting voice to emerging and rapidly growing global biotech companies and to contribute to awareness of biotech and support the biotech ecosystem at large. Up until 2023, the Biotech Social Pact was managed by Portland, a global Public Affairs company, with the financial support of Alnylam Pharmaceuticals, Amicus and argenx.